CU20090148A7 - 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso - Google Patents

4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso

Info

Publication number
CU20090148A7
CU20090148A7 CU20090148A CU20090148A CU20090148A7 CU 20090148 A7 CU20090148 A7 CU 20090148A7 CU 20090148 A CU20090148 A CU 20090148A CU 20090148 A CU20090148 A CU 20090148A CU 20090148 A7 CU20090148 A7 CU 20090148A7
Authority
CU
Cuba
Prior art keywords
naftiridinamides
dihidro
aril
replaced
diseases
Prior art date
Application number
CU20090148A
Other languages
English (en)
Other versions
CU23874B1 (es
Inventor
Adam Nitsche
Martina Klein
Elke Hartmann
Lars Baerfacker
Rolf Grosser
Barbara Albrecht
Klaus Muenter
Peter Kolkhof
Karl-Heinz Schlemmer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39512753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20090148(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CU20090148A7 publication Critical patent/CU20090148A7/es
Publication of CU23874B1 publication Critical patent/CU23874B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)

Abstract

La presente solicitud se refiere a nuevas 4-aril-1, 4-dihidro-1,6-naftiridin-3carboxamidas sustituidas, a procedimientos para su preparación, a su uso para el tratamiento y/o la profilaxis de enfermedades, así como a su uso para la preparación de fármacos para el tratamiento y/o la profilaxis de enfermedades, especialmente de enfermedades cardiovasculares.
CUP2009000148A 2007-02-27 2009-08-14 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso CU23874B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007009494A DE102007009494A1 (de) 2007-02-27 2007-02-27 Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
PCT/EP2008/001257 WO2008104306A2 (de) 2007-02-27 2008-02-19 Substituierte 4-aryl-1,4-dihydro-1,6-naphthyridinamide und ihre verwendung

Publications (2)

Publication Number Publication Date
CU20090148A7 true CU20090148A7 (es) 2011-04-26
CU23874B1 CU23874B1 (es) 2013-04-19

Family

ID=39512753

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2009000148A CU23874B1 (es) 2007-02-27 2009-08-14 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso

Country Status (45)

Country Link
US (2) US8436180B2 (es)
EP (1) EP2132206B1 (es)
JP (2) JP5367586B2 (es)
KR (1) KR101614164B1 (es)
CN (1) CN101641352B (es)
AR (1) AR065463A1 (es)
AU (1) AU2008221071B2 (es)
BR (2) BRPI0808098B8 (es)
CA (1) CA2679232C (es)
CL (1) CL2008000502A1 (es)
CO (1) CO6220951A2 (es)
CR (1) CR10976A (es)
CU (1) CU23874B1 (es)
CY (1) CY1116455T1 (es)
DE (1) DE102007009494A1 (es)
DK (1) DK2132206T3 (es)
DO (1) DOP2009000205A (es)
EC (1) ECSP099581A (es)
ES (1) ES2540803T3 (es)
FR (1) FR22C1017I2 (es)
GT (1) GT200900230A (es)
HK (1) HK1140194A1 (es)
HN (1) HN2009001597A (es)
HR (1) HRP20150702T1 (es)
HU (2) HUE026441T2 (es)
IL (1) IL200060A (es)
JO (1) JO3018B1 (es)
LT (1) LTPA2022512I1 (es)
MA (1) MA31245B1 (es)
MX (1) MX2009008701A (es)
MY (2) MY150748A (es)
NL (1) NL301192I2 (es)
NZ (1) NZ579230A (es)
PA (1) PA8770101A1 (es)
PE (1) PE20090724A1 (es)
PL (1) PL2132206T3 (es)
PT (1) PT2132206E (es)
SA (1) SA08290071B1 (es)
SI (1) SI2132206T1 (es)
TN (1) TN2009000318A1 (es)
TW (2) TWI415608B (es)
UA (1) UA102065C2 (es)
UY (3) UY30931A1 (es)
WO (1) WO2008104306A2 (es)
ZA (1) ZA200905730B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2995317A1 (en) 2010-05-26 2016-03-16 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN107375291A (zh) 2011-10-28 2017-11-24 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
MX354242B (es) 2011-10-28 2018-02-20 Lumena Pharmaceuticals Inc Nhibidores de la recirculación de ácidos biliares para el tratamiento de enfermedades hepáticas colestásicas pediátricas.
US10156567B2 (en) 2012-12-17 2018-12-18 General Electric Company In-vitro magnetic resonance detection of a target substance without separating bound magnetic nanoparticles from unbound magnetic nanoparticles
JP2016514678A (ja) 2013-03-15 2016-05-23 ルメナ ファーマシューティカルズ エルエルシー バレット食道と胃食道逆流性疾患を処置するための胆汁酸再利用阻害剤
MX2015013193A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores del reciclaje de acidos biliares para el tratamiento de colangitis esclerosante primaria y enfermedad inflamatoria intestinal.
CN103193704B (zh) * 2013-04-12 2016-03-09 四川铂瑞生物医药有限公司 2-羟基-4-氨基-5-甲基吡啶杂环化合物
EA029518B1 (ru) 2014-06-30 2018-04-30 Астразенека Аб Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора
CN106795155B (zh) * 2014-08-01 2023-06-16 拜耳医药股份有限公司 一种化合物的制备方法及其纯化以用作活性药物成分
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
EP3337799A1 (de) * 2015-08-21 2018-06-27 Bayer Pharma Aktiengesellschaft Verfahren zur herstellung der metaboliten von (4s) und (4r)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamid und deren verwendung
ES2739904T3 (es) * 2015-08-21 2020-02-04 Bayer Pharma AG Procedimiento para la preparación de (4S)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para el uso como principio activo farmacéutico
PE20180555A1 (es) * 2015-08-21 2018-04-02 Bayer Pharma AG Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de metodos electroquimicos
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
MX2018006474A (es) 2015-12-02 2018-08-01 Syngenta Participations Ag Derivados de oxadiazol microbicidas.
ES2973248T3 (es) 2016-07-26 2024-06-19 Inst Nat Sante Rech Med Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis
EP3525779B1 (de) 2016-10-11 2024-06-05 Bayer Pharma Aktiengesellschaft Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone
CN109890379A (zh) * 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
WO2018153898A1 (de) * 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten
WO2018219825A1 (en) 2017-06-02 2018-12-06 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
DE102017008472A1 (de) 2017-09-08 2018-05-03 Bayer Pharma Aktiengesellschaft Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten
CN109721536B (zh) * 2017-10-27 2020-11-24 广东东阳光药业有限公司 苯基取代的稠合三环类化合物及其用途
EP3560922A1 (de) 2018-04-24 2019-10-30 Bayer Aktiengesellschaft Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid durch racemat-spaltung mittels diastereomerer weinsäureester
WO2019223629A1 (zh) * 2018-05-22 2019-11-28 广东东阳光药业有限公司 苯基取代的二氢萘啶类化合物及其用途
CN110917195A (zh) * 2018-08-20 2020-03-27 山西惠尔健生物科技有限公司 肌松剂阿库氯铵（Alcuronium chloride）可作为抗心律失常药物
JP2022519905A (ja) 2019-02-12 2022-03-25 ミルム ファーマシューティカルズ インコーポレイテッド 胆汁酸塩排出ポンプ欠損症の患者における遺伝子型およびａｓｂｔｉに対する用量依存的反応
PE20220251A1 (es) 2019-03-05 2022-02-16 Bayer Ag Procedimiento para la preparacion de 4-amino-5-metilpiridona
SG11202109546RA (en) 2019-03-05 2021-09-29 Bayer Ag Synthesis of 4-amino-5-methyl-1h-pyridin-2(1h)-on (intermediate compound for the synthesis of the mr antagonist finerenone) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using the intermediate compound 2-chloro-5-methyl-4-pyridinamine
PE20221420A1 (es) * 2019-10-17 2022-09-20 Bayer Ag Procedimiento fotoquimico para la preparacion de (4r,4s)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxamida
JOP20220148A1 (ar) * 2019-10-17 2023-01-30 Bayer Ag عملية لانتاج استرات أسيلوكسي مثيل من حمض (4s)- (4-سيانو-2-ميثوكسي فنيل)-5-ايثوكسي-2، 8-ثنائي مثيل-1، 4-ثنائي هيدرو-1، 6-نفثيريدين-3-كربوكسيليك
CA3158165A1 (en) * 2019-10-17 2021-04-22 Bayer Aktiengesellschaft Process for the preparation of (2-cyanoethyl (4s)-4-(4-cyano-2-methoxy-phenyl)-5-hydroxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxylate by racemate separation by means of diastereomeric tartaric acid esters
CR20220157A (es) * 2019-10-17 2022-06-02 Bayer Ag Procedimiento para preparar (4s)–4–(4–ciano–2–metoxi–fenil)–5–etoxi–2,8–dimetil–1,4–dihidro–1,6–naftiridin–3–carboxilato de 2–cianoetilo mediante separación de racematos utilizando ésteres diastereoméricos de ácido tartárico
JP2023518168A (ja) 2020-03-11 2023-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。
JP2023523596A (ja) 2020-04-22 2023-06-06 バイエル アクチェンゲゼルシャフト 心血管疾患および／または腎疾患を治療および／または予防するためのフィネレノンとｓｇｌｔ２阻害剤の組み合わせ
EP3900722A1 (en) 2020-04-22 2021-10-27 Bayer AG Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases
WO2021213493A1 (zh) * 2020-04-24 2021-10-28 东莞市东阳光新药研发有限公司 二氢萘啶类化合物的晶型及其用途
CN113549066B (zh) * 2020-04-24 2023-07-21 年衍药业(珠海)有限公司 二氢萘啶类化合物的晶型及其用途
WO2021254896A1 (en) 2020-06-16 2021-12-23 Bayer Aktiengesellschaft Process for preparing (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide enabled by a catalytic asymmetric hantzsch ester reduction
WO2022214206A1 (en) 2021-04-08 2022-10-13 Bayer Aktiengesellschaft Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases
WO2023004002A1 (en) * 2021-07-21 2023-01-26 Cyta Therapeutics, Inc. Particle delivery of thyroid hormone receptor agonists and antagonists
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
TW202328127A (zh) * 2021-09-18 2023-07-16 大陸商上海拓界生物醫藥科技有限公司 取代的１，４－二氫－１，６－萘啶醯胺及其用途
CN114149427A (zh) * 2021-12-18 2022-03-08 上海鼎雅药物化学科技有限公司 非奈利酮及其中间体的合成方法
WO2023205164A1 (en) 2022-04-18 2023-10-26 Teva Pharmaceuticals International Gmbh Processes for the preparation of finerenone
EP4286368A1 (de) 2022-05-31 2023-12-06 Bayer Aktiengesellschaft Verfahren zur herstellung von 4-formyl-3-methoxybenzonitril
WO2024022481A1 (zh) * 2022-07-29 2024-02-01 苏中药业集团股份有限公司 苯基取代的二氢萘啶类化合物及其制备与用途
WO2024110523A1 (en) 2022-11-23 2024-05-30 Bayer Aktiengesellschaft Treatment of chronic kidney disease in type i diabetes mellitus
WO2024126694A1 (en) 2022-12-16 2024-06-20 Bayer Aktiengesellschaft Sequential one-pot synthesis for preparing 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
CN116715664A (zh) * 2023-06-12 2023-09-08 常州制药厂有限公司 一种非奈利酮关键中间体的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698341A (en) * 1983-07-30 1987-10-06 Godecke Aktiengesellschaft Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis
DE3327650A1 (de) 1983-07-30 1985-02-14 Gödecke AG, 1000 Berlin 1,6-naphthyridinon-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von gefaesserkrankungen
DE3502831A1 (de) 1985-01-29 1986-07-31 Gödecke AG, 1000 Berlin 1,6-naphthyridinon-derivate, verfahren zu deren herstellung und deren verwendung
IL75987A (en) 1984-08-25 1991-07-18 Goedecke Ag Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
US4760081A (en) * 1984-08-25 1988-07-26 Goedecke Aktiengesellschaft 1,6-naphthyridine derivatives useful for treating diseases of the blood vessels
DE3431303A1 (de) 1984-08-25 1986-02-27 Goedecke Ag 1,6-naphthyridin-derivate, verfahren zu deren herstellung und deren verwendung
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
JP2004505081A (ja) 2000-08-02 2004-02-19 アボット・ラボラトリーズ ジヒドロナフチリジンカリウムチャンネルオープナー
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
DE102004012365A1 (de) 2004-03-13 2005-09-29 Bayer Healthcare Ag Substituierte Dihydropyridine
JP2007230869A (ja) 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
WO2006066011A2 (en) 2004-12-13 2006-06-22 Irm Llc Compounds and compositions as modulators of steroidal receptors and calcium channel activities
DE602006020138D1 (de) 2005-06-29 2011-03-31 Compumedics Ltd Sensoranordnung mit leitfähiger brücke
DE102005034264A1 (de) 2005-07-22 2007-02-01 Bayer Healthcare Ag 4-Chromenonyl-1,4-dihydropyridincarbonitrile und ihre Verwendung
DE102006026583A1 (de) * 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
DE102006026585A1 (de) * 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Substituierte 4-Aryl-1,4-dihydro-1,6-naphthyridine und ihre Verwendung

Also Published As

Publication number Publication date
BRPI0808098A2 (pt) 2014-06-17
CN101641352A (zh) 2010-02-03
TW200843755A (en) 2008-11-16
ES2540803T3 (es) 2015-07-13
BRPI0808098B8 (pt) 2021-05-25
DE102007009494A1 (de) 2008-08-28
RU2009135659A (ru) 2011-04-10
BRPI0808098B1 (pt) 2020-08-04
DOP2009000205A (es) 2010-02-28
KR20090129992A (ko) 2009-12-17
FR22C1017I1 (fr) 2022-06-17
ECSP099581A (es) 2009-09-29
PL2132206T3 (pl) 2015-08-31
DK2132206T3 (en) 2015-07-06
MX2009008701A (es) 2009-08-27
FR22C1017I2 (fr) 2023-02-03
CO6220951A2 (es) 2010-11-19
NZ579230A (en) 2012-04-27
TW201340968A (zh) 2013-10-16
PA8770101A1 (es) 2009-05-15
CA2679232A1 (en) 2008-09-04
BR122020008544B1 (pt) 2021-02-17
JO3018B1 (ar) 2016-09-05
WO2008104306A3 (de) 2009-03-19
CU23874B1 (es) 2013-04-19
BR122020008544B8 (pt) 2021-07-27
JP5367586B2 (ja) 2013-12-11
JP2014012678A (ja) 2014-01-23
EP2132206B1 (de) 2015-04-01
CY1116455T1 (el) 2017-03-15
LTPA2022512I1 (es) 2022-07-11
UY38953A (es) 2021-08-31
TWI415608B (zh) 2013-11-21
TN2009000318A1 (en) 2010-12-31
US20140100243A1 (en) 2014-04-10
MY176873A (en) 2020-08-25
EP2132206A2 (de) 2009-12-16
GT200900230A (es) 2011-11-29
CN101641352B (zh) 2013-11-20
UY30931A1 (es) 2008-09-30
JP2010519232A (ja) 2010-06-03
SI2132206T1 (sl) 2015-08-31
TWI474821B (zh) 2015-03-01
SA08290071B1 (ar) 2012-11-03
HUS2200015I1 (hu) 2022-06-28
AR065463A1 (es) 2009-06-10
JP5752754B2 (ja) 2015-07-22
AU2008221071A1 (en) 2008-09-04
HUE026441T2 (en) 2016-06-28
AU2008221071B2 (en) 2014-01-16
PT2132206E (pt) 2015-08-04
HN2009001597A (es) 2012-01-16
KR101614164B1 (ko) 2016-04-20
CA2679232C (en) 2016-07-05
HRP20150702T1 (hr) 2015-08-14
PE20090724A1 (es) 2009-07-17
RU2470932C2 (ru) 2012-12-27
IL200060A0 (en) 2010-04-15
MY150748A (en) 2014-02-28
MA31245B1 (fr) 2010-03-01
CL2008000502A1 (es) 2008-06-13
US9051316B2 (en) 2015-06-09
HK1140194A1 (en) 2010-10-08
UY38952A (es) 2021-08-31
US20100136142A1 (en) 2010-06-03
US8436180B2 (en) 2013-05-07
IL200060A (en) 2016-07-31
CR10976A (es) 2010-01-13
UA102065C2 (en) 2013-06-10
ZA200905730B (en) 2010-10-27
WO2008104306A2 (de) 2008-09-04
NL301192I2 (nl) 2022-12-07

Similar Documents

Publication Publication Date Title
CU20090148A7 (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
DOP2011000285A (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
ECSP12012310A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
UY29099A1 (es) Fenilaminotiazoles sustituidos y su uso
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
ECSP11011483A (es) Piperidinas sustituidas
DOP2006000280A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y su uso
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
CR20110627A (es) Piperidinas sustituidas
CL2011002930A1 (es) Compuestos derivados de 8-oxo-9-[3-(1h-bencimidazol-2-iloxi)-fenil]-4,5,6,7,8,9-hexahidro-2h-pirrolo[3,4-b]quinolina-3-carboxilato de etilo; procedimiento de preparacion; composicion farmaceutica que lo comprende; compuestos intermediarios; y uso del compuesto como inhibidor selectivo de quinasas aurora a y b para tratar el cancer.
DOP2005000174A (es) Fenilaminotiazoles sustituidos y su uso
CU20100260A7 (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
DOP2009000093A (es) Dihidropirazolonas sustituídas para el tratamiento de enfermedades cardiovasculares y hematológicas

Legal Events

Date Code Title Description
FG Grant of patent